PROVIDENCE, R.I., Dec. 7, 2024 — EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, concludes 2024 with significant advancements in scientific innovation, service expansion, and company growth.
This year, EpiVax broadened its immunogenicity risk assessment services by introducing numerous new capabilities within the ISPRI
(Immunogenicity Screening and Protein Re-engineering Interface) Toolkit and various assessment offerings.
Specifically, EpiVax launched the ISPRI , , , , , , and Design fee-for-service analyses. These options evaluate biologic modalities at various preclinical development stages, allowing for candidate ranking, modality-specific benchmarking, sequence optimization, and comprehensive risk analysis with improved accuracy.
Furthermore, EpiVax enhanced its program supporting sponsors using the FDA’s Abbreviated New Drug Application (ANDA) pathway for generic peptides and their impurities. Key improvements included advanced adaptive in vitro assay offerings and [REDACTED], establishing EpiVax as a comprehensive provider (in silico, in vitro, and innate assessment) for generic drug developers. A collaboration with [REDACTED] resulted in the development of standardized controls for T cell assays, aiming to enhance assay specificity and sensitivity across the industry.
This work complemented substantial contributions to the field through [REDACTED] by the EpiVax team in 2024.
The expanded offerings resulted in a nearly 60% increase in EpiVax immunogenicity risk assessment bookings compared to 2023, fueled by a doubling of new clients across the ISPRI Access, ISPRI Fee-for-Service, and PANDA® service areas. This growth facilitated an 18% increase in headcount, including strategic leadership appointments to support the company’s new offerings.
Looking ahead to 2025, guided by almost three decades of “fearless science”, EpiVax plans to build upon this year’s success by further integrating artificial intelligence and machine learning into existing platforms, expanding laboratory capabilities, and adding new scientific expertise to be announced next year.
About EpiVax
EpiVax is a leader in preclinical immunogenicity assessment and sequence optimization for peptide therapeutics, biologic therapeutics, and vaccines. EpiVax collaborates with a global network of companies, agencies, and academics to accelerate immunogenicity risk assessment, immune modulation, and rapid vaccine design.
Press Contact
Sarah Moniz
Director, Business Development
EpiVax
[REDACTED]
Logo –